Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| TEVA PHARMACEUTICAL INDUSTRIES LTDTEVA · Entity 3063 | Chief Accounting Officer | August 21, 2026 | August 25, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
TEVA PHARMACEUTICAL INDUSTRIES LTD
Report date August 21, 2026 · Filed August 25, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 13,071 |
Last balance in matching sequence
After 2026-08-21 transaction · row 3
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
3 source rowsRow 1 · 2026-08-21 · Sale · Disposed 6,945 · Balance 13,071 F1: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.61 to $31.62, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. Row 2 · 2026-08-21 · Exercise / conversion · Acquired 2,500 · Balance 15,571 F1: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Row 3 · 2026-08-21 · Sale · Disposed 2,500 · Balance 13,071 F1: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. |
| Stock Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $19.16 · Expires 2028-03-02 | Direct | 7,502 |
Reported balance
After 2026-08-21 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-08-21 · Exercise / conversion · Disposed 2,500 · Balance 7,502 F3: Stock options were granted on March 3, 2018, with 2,500 having vested on each of March 2, 2019, March 2, 2020 and March 2, 2021 and 2,502 having vested on March 2, 2022. F1: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. |
Filing footnotes · ownership attribution and instrument terms
F1: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.61 to $31.62, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.
F3: Stock options were granted on March 3, 2018, with 2,500 having vested on each of March 2, 2019, March 2, 2020 and March 2, 2021 and 2,502 having vested on March 2, 2022.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 21, 2026 Filed Aug 25, 2026 20:05 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionStock Options (right to buy) · Derivative | 2,500 | $19.16 Strike: $19.16 | $47,900.00 |
DisclosureSEC source: 0001193125-26-365116 · ownership.xml · derivative · entry 4 Weiss Amir · CIK 0001897057 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,502 Underlying: Ordinary Shares · 2,500 shares Expires 2028-03-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Stock options were granted on March 3, 2018, with 2,500 having vested on each of March 2, 2019, March 2, 2020 and March 2, 2021 and 2,502 having vested on March 2, 2022. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| August 21, 2026 Filed Aug 25, 2026 20:05 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | SaleOrdinary Shares | 2,500 | $37.63 | $94,076.75 |
DisclosureSEC source: 0001193125-26-365116 · ownership.xml · nonDerivative · entry 3 Weiss Amir · CIK 0001897057 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,071 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| August 21, 2026 Filed Aug 25, 2026 20:05 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 2,500 | $19.61 | $49,025.00 |
DisclosureSEC source: 0001193125-26-365116 · ownership.xml · nonDerivative · entry 2 Weiss Amir · CIK 0001897057 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,571 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| August 21, 2026 Filed Aug 25, 2026 20:05 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | SaleOrdinary Shares | 6,945 | $37.61 | $261,224.37 |
DisclosureSEC source: 0001193125-26-365116 · ownership.xml · nonDerivative · entry 1 Weiss Amir · CIK 0001897057 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,071 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.61 to $31.62, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| May 06, 2026 Filed May 7, 2026 20:03 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | SaleOrdinary Shares | 10,679 | $36.00 | $384,444.00 |
DisclosureSEC source: 0001193125-26-211855 · ownership.xml · nonDerivative · entry 1 Weiss Amir · CIK 0001897057 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,016 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| March 05, 2026 Filed Mar 9, 2026 20:19 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 3,537 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-098560 · ownership.xml · derivative · entry 2 Weiss Amir · CIK 0001897057 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,613 Underlying: Ordinary Shares · 3,537 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F3 · derivative.exercise_date: Restricted share units were granted on March 5, 2025, with 3,537 vested on March 5, 2026, 3,537 vesting on each of March 5, 2027 and March 5, 2028, and 3,539 vesting on March 5, 2029. F3 · derivative.expiration_date: Restricted share units were granted on March 5, 2025, with 3,537 vested on March 5, 2026, 3,537 vesting on each of March 5, 2027 and March 5, 2028, and 3,539 vesting on March 5, 2029. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| March 05, 2026 Filed Mar 9, 2026 20:19 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 3,537 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-098560 · ownership.xml · nonDerivative · entry 1 Weiss Amir · CIK 0001897057 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,695 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| March 04, 2026 Filed Mar 6, 2026 21:01 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | GrantRestricted Share Units · Derivative | 11,280 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-096459 · ownership.xml · derivative · entry 5 Weiss Amir · CIK 0001897057 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,280 Underlying: Ordinary Shares · 11,280 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F5 · derivative.exercise_date: Restricted share units were granted on March 4, 2026, with 2,820 vesting on each of March 4, 2027, March 4, 2028, March 4, 2029 and March 4, 2030. F5 · derivative.expiration_date: Restricted share units were granted on March 4, 2026, with 2,820 vesting on each of March 4, 2027, March 4, 2028, March 4, 2029 and March 4, 2030. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| March 04, 2026 Filed Mar 6, 2026 21:01 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 5,650 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-096459 · ownership.xml · derivative · entry 4 Weiss Amir · CIK 0001897057 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,300 Underlying: Ordinary Shares · 5,650 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F4 · derivative.exercise_date: Restricted share units were granted on March 4, 2024, with 5,650 vested on each of March 4, 2025 and March 4, 2026, and 5,650 vesting on each of March 4, 2027 and March 4, 2028. F4 · derivative.expiration_date: Restricted share units were granted on March 4, 2024, with 5,650 vested on each of March 4, 2025 and March 4, 2026, and 5,650 vesting on each of March 4, 2027 and March 4, 2028. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| March 04, 2026 Filed Mar 6, 2026 21:01 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 10,679 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-096459 · ownership.xml · derivative · entry 3 Weiss Amir · CIK 0001897057 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 10,679 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F3 · derivative.exercise_date: Restricted share units were granted on March 4, 2022, with 10,676 vested on each of March 4, 2023, March 4, 2024 and March 4, 2025, and 10,679 vested on March 4, 2026. F3 · derivative.expiration_date: Restricted share units were granted on March 4, 2022, with 10,676 vested on each of March 4, 2023, March 4, 2024 and March 4, 2025, and 10,679 vested on March 4, 2026. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| March 04, 2026 Filed Mar 6, 2026 21:01 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 5,650 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-096459 · ownership.xml · nonDerivative · entry 2 Weiss Amir · CIK 0001897057 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,158 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| March 04, 2026 Filed Mar 6, 2026 21:01 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 10,679 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-096459 · ownership.xml · nonDerivative · entry 1 Weiss Amir · CIK 0001897057 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,508 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| March 03, 2026 Filed Mar 5, 2026 21:11 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 5,179 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-093963 · ownership.xml · derivative · entry 2 Weiss Amir · CIK 0001897057 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,180 Underlying: Ordinary Shares · 5,179 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F3 · derivative.exercise_date: Restricted share units were granted on March 3, 2023, with 5,179 vested on each of March 3, 2024, March 3, 2025 and March 3, 2026, and 5,180 vesting on March 3, 2027. F3 · derivative.expiration_date: Restricted share units were granted on March 3, 2023, with 5,179 vested on each of March 3, 2024, March 3, 2025 and March 3, 2026, and 5,180 vesting on March 3, 2027. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| March 03, 2026 Filed Mar 5, 2026 21:11 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 5,179 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-093963 · ownership.xml · nonDerivative · entry 1 Weiss Amir · CIK 0001897057 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,829 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| December 16, 2025 Filed Dec 18, 2025 21:04 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | SaleOrdinary Shares | 12,300 | $30.20 | $371,504.28 |
DisclosureSEC source: 0001193125-25-324789 · ownership.xml · nonDerivative · entry 1 Weiss Amir · CIK 0001897057 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,650 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.20 to $30.205, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| November 06, 2025 Filed Nov 10, 2025 21:06 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | SaleOrdinary Shares | 12,300 | $24.44 | $300,564.03 |
DisclosureSEC source: 0001193125-25-274204 · ownership.xml · nonDerivative · entry 1 Weiss Amir · CIK 0001897057 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,950 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.435 to $24.455, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 05, 2025 Filed Mar 7, 2025 21:29 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | GrantRestricted Share Units · Derivative | 14,150 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-035542 · ownership.xml · derivative · entry 3 Weiss Amir · CIK 0001897057 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,150 Underlying: Ordinary Shares · 14,150 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F4 · derivative.exercise_date: Restricted share units were granted on March 5, 2025, with 3,537 vesting on each of March 5, 2026, March 5, 2027 and March 5, 2028, and 3,539 vesting on March 5, 2029. F4 · derivative.expiration_date: Restricted share units were granted on March 5, 2025, with 3,537 vesting on each of March 5, 2026, March 5, 2027 and March 5, 2028, and 3,539 vesting on March 5, 2029. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| March 05, 2025 Filed Mar 7, 2025 21:29 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 3,566 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-035542 · ownership.xml · derivative · entry 2 Weiss Amir · CIK 0001897057 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 3,566 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F3 · derivative.exercise_date: Restricted share units were granted on March 5, 2021, with 3,564 vested on each of March 5, 2022, March 5, 2023 and March 5, 2024, and 3,566 vested on March 5, 2025. F3 · derivative.expiration_date: Restricted share units were granted on March 5, 2021, with 3,564 vested on each of March 5, 2022, March 5, 2023 and March 5, 2024, and 3,566 vested on March 5, 2025. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| March 05, 2025 Filed Mar 7, 2025 21:29 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 3,566 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-035542 · ownership.xml · nonDerivative · entry 1 Weiss Amir · CIK 0001897057 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,250 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| March 04, 2025 Filed Mar 6, 2025 21:21 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 5,650 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-034707 · ownership.xml · derivative · entry 4 Weiss Amir · CIK 0001897057 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,950 Underlying: Ordinary Shares · 5,650 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F4 · derivative.exercise_date: Restricted share units were granted on March 4, 2024, with 5,650 vested on March 4, 2025, and 5,650 vesting on each of March 4, 2026, March 4, 2027 and March 4, 2028. F4 · derivative.expiration_date: Restricted share units were granted on March 4, 2024, with 5,650 vested on March 4, 2025, and 5,650 vesting on each of March 4, 2026, March 4, 2027 and March 4, 2028. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| March 04, 2025 Filed Mar 6, 2025 21:21 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 10,676 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-034707 · ownership.xml · derivative · entry 3 Weiss Amir · CIK 0001897057 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,679 Underlying: Ordinary Shares · 10,676 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F3 · derivative.exercise_date: Restricted share units were granted on March 4, 2022, with 10,676 vested on each of March 4, 2023, March 4, 2024 and March 4, 2025, and 10,679 vesting on March 4, 2027. F3 · derivative.expiration_date: Restricted share units were granted on March 4, 2022, with 10,676 vested on each of March 4, 2023, March 4, 2024 and March 4, 2025, and 10,679 vesting on March 4, 2027. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| March 04, 2025 Filed Mar 6, 2025 21:21 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 5,650 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-034707 · ownership.xml · nonDerivative · entry 2 Weiss Amir · CIK 0001897057 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,684 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| March 04, 2025 Filed Mar 6, 2025 21:21 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 10,676 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-034707 · ownership.xml · nonDerivative · entry 1 Weiss Amir · CIK 0001897057 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,034 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| March 03, 2025 Filed Mar 5, 2025 21:20 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 5,179 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-033628 · ownership.xml · derivative · entry 2 Weiss Amir · CIK 0001897057 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,359 Underlying: Ordinary Shares · 5,179 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F3 · derivative.exercise_date: Restricted share units were granted on March 3, 2023, with 5,179 vested on each of March 3, 2024 and March 3, 2025, 5,179 vesting on March 3, 2026, and 5,180 vesting on March 3, 2027. F3 · derivative.expiration_date: Restricted share units were granted on March 3, 2023, with 5,179 vested on each of March 3, 2024 and March 3, 2025, 5,179 vesting on March 3, 2026, and 5,180 vesting on March 3, 2027. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| March 03, 2025 Filed Mar 5, 2025 21:20 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 5,179 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-033628 · ownership.xml · nonDerivative · entry 1 Weiss Amir · CIK 0001897057 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,358 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| May 16, 2024 Filed May 17, 2024 11:41 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | SaleOrdinary Shares | 12,635 | $16.65 | $210,376.54 |
DisclosureSEC source: 0000950170-24-061334 · ownership.xml · nonDerivative · entry 2 Weiss Amir · CIK 0001897057 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,179 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.65 to $16.655, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| May 15, 2024 Filed May 17, 2024 11:41 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | SaleOrdinary Shares | 15,500 | $16.80 | $260,417.05 |
DisclosureSEC source: 0000950170-24-061334 · ownership.xml · nonDerivative · entry 1 Weiss Amir · CIK 0001897057 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,814 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.800 to $16.805, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 05, 2024 Filed Mar 7, 2024 21:08 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 3,564 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-027944 · ownership.xml · derivative · entry 2 Weiss Amir · CIK 0001897057 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,566 Underlying: Ordinary Shares · 3,564 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F3 · derivative.exercise_date: Restricted share units were granted on March 5, 2021, with 3,564 vested on each of March 5, 2022 and March 5, 2023, 3,564 vesting on March 5, 2024, and 3,566 vesting on March 5, 2025. F3 · derivative.expiration_date: Restricted share units were granted on March 5, 2021, with 3,564 vested on each of March 5, 2022 and March 5, 2023, 3,564 vesting on March 5, 2024, and 3,566 vesting on March 5, 2025. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| March 05, 2024 Filed Mar 7, 2024 21:08 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 3,564 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-027944 · ownership.xml · nonDerivative · entry 1 Weiss Amir · CIK 0001897057 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,314 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| March 04, 2024 Filed Mar 5, 2024 21:03 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | GrantRestricted Share Units · Derivative | 22,600 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-025863 · ownership.xml · derivative · entry 5 Weiss Amir · CIK 0001897057 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,600 Underlying: Ordinary Shares · 22,600 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F5 · derivative.exercise_date: Restricted share units were granted on March 4, 2024, with 5,650 vesting on each of March 4, 2025, March 4, 2026, March 4, 2027, and March 4, 2028. F5 · derivative.expiration_date: Restricted share units were granted on March 4, 2024, with 5,650 vesting on each of March 4, 2025, March 4, 2026, March 4, 2027, and March 4, 2028. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| March 04, 2024 Filed Mar 5, 2024 21:03 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 10,676 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-025863 · ownership.xml · derivative · entry 4 Weiss Amir · CIK 0001897057 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,355 Underlying: Ordinary Shares · 10,676 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F4 · derivative.exercise_date: Restricted share units were granted on March 4, 2022, with 10,676 vested on March 4, 2023 and March 4, 2024, 10, 676 vesting on March 4, 2025 and 10,679 vesting on March 4, 2026. F4 · derivative.expiration_date: Restricted share units were granted on March 4, 2022, with 10,676 vested on March 4, 2023 and March 4, 2024, 10, 676 vesting on March 4, 2025 and 10,679 vesting on March 4, 2026. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| March 04, 2024 Filed Mar 5, 2024 21:03 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 10,676 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-025863 · ownership.xml · nonDerivative · entry 2 Weiss Amir · CIK 0001897057 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,750 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| March 03, 2024 Filed Mar 5, 2024 21:03 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 5,179 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-025863 · ownership.xml · derivative · entry 3 Weiss Amir · CIK 0001897057 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,538 Underlying: Ordinary Shares · 5,179 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F3 · derivative.exercise_date: Restricted share units were granted on March 3, 2023, with 5,179 vesting on each of March 3, 2024, March 3, 2025 and March 3, 2026, and 5,180 vesting on March 3, 2027. F3 · derivative.expiration_date: Restricted share units were granted on March 3, 2023, with 5,179 vesting on each of March 3, 2024, March 3, 2025 and March 3, 2026, and 5,180 vesting on March 3, 2027. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| March 03, 2024 Filed Mar 5, 2024 21:03 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 5,179 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-025863 · ownership.xml · nonDerivative · entry 1 Weiss Amir · CIK 0001897057 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,074 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| February 28, 2024 Filed Mar 1, 2024 11:48 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 3,219 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-023526 · ownership.xml · derivative · entry 2 Weiss Amir · CIK 0001897057 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 3,219 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F3 · derivative.exercise_date: Restricted share units were granted on February 28, 2020 with 3,219 vesting on each of February 28, 2021, February 28, 2022, February 28, 2023, and February 28, 2024. F3 · derivative.expiration_date: Restricted share units were granted on February 28, 2020 with 3,219 vesting on each of February 28, 2021, February 28, 2022, February 28, 2023, and February 28, 2024. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| February 28, 2024 Filed Mar 1, 2024 11:48 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 3,219 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-023526 · ownership.xml · nonDerivative · entry 1 Weiss Amir · CIK 0001897057 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,895 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| February 01, 2024 Filed Feb 5, 2024 12:49 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | SaleOrdinary Shares | 31,766 | $12.37 | $392,954.95 |
DisclosureSEC source: 0000950170-24-011009 · ownership.xml · nonDerivative · entry 1 Weiss Amir · CIK 0001897057 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,676 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.37 to $12.375, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| August 04, 2023 Filed Aug 7, 2023 20:15 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | SaleOrdinary Shares | 1,981.41 | $9.92 | $19,657.57 |
DisclosureSEC source: 0001209191-23-044806 · doc4.xml · nonDerivative · entry 1 Weiss Amir · CIK 0001897057 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,442 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.91 to $9.94, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 05, 2023 Filed Mar 7, 2023 21:15 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 3,564 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-016723 · doc4.xml · derivative · entry 7 Weiss Amir · CIK 0001897057 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,130 Underlying: Ordinary Shares · 3,564 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F6 · derivative.exercise_date: Restricted share units were granted on March 5, 2021, with 3,564 vested on each of March 5, 2022 and March 5, 2023, 3,564 vesting on March 5, 2024, and 3,566 vesting on March 5, 2025. F6 · derivative.expiration_date: Restricted share units were granted on March 5, 2021, with 3,564 vested on each of March 5, 2022 and March 5, 2023, 3,564 vesting on March 5, 2024, and 3,566 vesting on March 5, 2025. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| March 05, 2023 Filed Mar 7, 2023 21:15 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 3,564 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-016723 · doc4.xml · nonDerivative · entry 3 Weiss Amir · CIK 0001897057 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,204.41 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| March 04, 2023 Filed Mar 7, 2023 21:15 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 10,676 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-016723 · doc4.xml · derivative · entry 6 Weiss Amir · CIK 0001897057 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,031 Underlying: Ordinary Shares · 10,676 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F5 · derivative.exercise_date: Restricted share units were granted on March 4, 2022, with 10,676 vested on March 4, 2023, 10,676 vesting on each of March 4, 2024 and March 4, 2025, and 10,679 vesting on March 4, 2026. F5 · derivative.expiration_date: Restricted share units were granted on March 4, 2022, with 10,676 vested on March 4, 2023, 10,676 vesting on each of March 4, 2024 and March 4, 2025, and 10,679 vesting on March 4, 2026. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| March 04, 2023 Filed Mar 7, 2023 21:15 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 2,406 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-016723 · doc4.xml · derivative · entry 5 Weiss Amir · CIK 0001897057 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 2,406 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F4 · derivative.exercise_date: Restricted share units were granted on March 4, 2019, with 2,403 vested on each of March 4, 2021 and March 4, 2022, and 2,406 vested on March 4, 2023. F4 · derivative.expiration_date: Restricted share units were granted on March 4, 2019, with 2,403 vested on each of March 4, 2021 and March 4, 2022, and 2,406 vested on March 4, 2023. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| March 04, 2023 Filed Mar 7, 2023 21:15 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 10,676 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-016723 · doc4.xml · nonDerivative · entry 2 Weiss Amir · CIK 0001897057 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,640.41 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| March 04, 2023 Filed Mar 7, 2023 21:15 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 2,406 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-016723 · doc4.xml · nonDerivative · entry 1 Weiss Amir · CIK 0001897057 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,964.41 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| March 03, 2023 Filed Mar 7, 2023 21:15 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | GrantRestricted Share Units · Derivative | 20,717 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-016723 · doc4.xml · derivative · entry 4 Weiss Amir · CIK 0001897057 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,717 Underlying: Ordinary Shares · 20,717 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F3 · derivative.exercise_date: Restricted share units were granted on March 3, 2023, with 5,179 vesting on each of March 3, 2024, March 3, 2025 and March 3, 2026, and 5,180 vesting on March 3, 2027. F3 · derivative.expiration_date: Restricted share units were granted on March 3, 2023, with 5,179 vesting on each of March 3, 2024, March 3, 2025 and March 3, 2026, and 5,180 vesting on March 3, 2027. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| February 28, 2023 Filed Mar 2, 2023 12:39 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 3,219 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-014443 · doc4.xml · derivative · entry 2 Weiss Amir · CIK 0001897057 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,219 Underlying: Ordinary Shares · 3,219 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F3 · derivative.exercise_date: Restricted share units were granted on February 28, 2020 with 3,219 vested on each of February 28, 2021, February 28, 2022 and February 28, 2023, and 3,219 vesting on February 28, 2024. F3 · derivative.expiration_date: Restricted share units were granted on February 28, 2020 with 3,219 vested on each of February 28, 2021, February 28, 2022 and February 28, 2023, and 3,219 vesting on February 28, 2024. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| February 28, 2023 Filed Mar 2, 2023 12:39 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 3,219 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-014443 · doc4.xml · nonDerivative · entry 1 Weiss Amir · CIK 0001897057 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,777.41 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| March 05, 2022 Filed Mar 8, 2022 21:14 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 3,564 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-017066 · doc4.xml · derivative · entry 5 Weiss Amir · CIK 0001897057 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,694 Underlying: Ordinary Shares · 3,564 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F5 · derivative.exercise_date: Restricted share units were granted on March 5, 2021, with 3,564 having vested on March 5, 2022, 3,564 vesting on each of March 5, 2023 and March 5, 2024 and 3,566 vesting on March 5, 2025. F5 · derivative.expiration_date: Restricted share units were granted on March 5, 2021, with 3,564 having vested on March 5, 2022, 3,564 vesting on each of March 5, 2023 and March 5, 2024 and 3,566 vesting on March 5, 2025. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| March 05, 2022 Filed Mar 8, 2022 21:14 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 3,564 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-017066 · doc4.xml · nonDerivative · entry 2 Weiss Amir · CIK 0001897057 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,558.41 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| March 04, 2022 Filed Mar 8, 2022 21:14 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | GrantRestricted Share Units · Derivative | 42,707 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-017066 · doc4.xml · derivative · entry 4 Weiss Amir · CIK 0001897057 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,707 Underlying: Ordinary Shares · 42,707 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F4 · derivative.exercise_date: Restricted share units were granted on March 4, 2022, with 10,676 vesting on each of March 4, 2023, March 4, 2024 and March 4, 2025 and 10,679 vesting on March 4, 2026. F4 · derivative.expiration_date: Restricted share units were granted on March 4, 2022, with 10,676 vesting on each of March 4, 2023, March 4, 2024 and March 4, 2025 and 10,679 vesting on March 4, 2026. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.